Effects of lanreotide SR and Autogel on tumor mass in patients with acromegaly: a systematic review
- 3 February 2009
- journal article
- research article
- Published by Springer Science and Business Media LLC in Pituitary
- Vol. 13 (1), 60-67
- https://doi.org/10.1007/s11102-009-0169-z
Abstract
No abstract availableKeywords
This publication has 69 references indexed in Scilit:
- Growth Hormone, Insulin-Like Growth Factors, and the SkeletonEndocrine Reviews, 2008
- Optimalization and cost management of lanreotide-Autogel therapy in acromegalyActa Endocrinologica, 2007
- Home administration of lanreotide Autogel® by patients with acromegaly, or their partners, is safe and effectiveClinical Endocrinology, 2007
- Long‐term (up to 18 years) effects on GH/IGF‐1 hypersecretion and tumour size of primary somatostatin analogue (SSTa) therapy in patients with GH‐secreting pituitary adenoma responsive to SSTaClinical Endocrinology, 2007
- Efficacy of lanreotide Autogel® administered every 4–8 weeks in patients with acromegaly previously responsive to lanreotide microparticles 30 mg: a phase III trialClinical Endocrinology, 2006
- Effectiveness and tolerability of 3-year lanreotide AutogelR treatment in patients with acromegalyClinical Endocrinology, 2006
- Consensus statement: medical management of acromegalyActa Endocrinologica, 2005
- Pharmacokinetic profile of lanreotide Autogel® in patients with acromegaly after four deep subcutaneous injections of 60, 90 or 120 mg every 28 daysClinical Endocrinology, 2005
- Somatostatin Receptor-Specific Analogs: Effects on Cell Proliferation and Growth Hormone Secretion in Human Somatotroph TumorsJournal of Clinical Endocrinology & Metabolism, 2001
- Slow release lanreotide treatment in acromegalic patients previously normalized by octreotideJournal of Clinical Endocrinology & Metabolism, 1994